An interim India-US trade arrangement offers clarity to India’s pharma sector, keeping medicines out of reciprocal tariffs. Washington has signaled negotiated outcomes for generics under the Section 232 investigation, which examines imports for national security threats. This agreement is seen as reassuring for strengthening the partnership and ensuring medicine security.
